Site icon pharmaceutical daily

World CRISPR Gene Detection and Diagnostic Markets 2023-2027 by Research, Clinical Lab, Consumer, Public Service with Executive and Consultant Guides – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides. 2023 to 2027” report has been added to ResearchAndMarkets.com’s offering.


Make investment decisions and valuations with confidence using the latest data.

CRISPR is not just about changing genes. CRISPR identifies unique genetic material instantly, accurately and cheaply. A whole new world of identification and diagnostics opens up. Find out exactly what kind of cold or flu you have. Find out exactly what kind of fish you are eating. Instantly detect the presence of unwelcome bacteria, anywhere. New COVID tests are already available.

Will this disruptive technology change the world of In Vitro Diagnostics? What is the impact on Clinical Laboratories? How will social norms be affected?

The market has just gotten started with a handful of small startup companies. Expect the big players to start taking notice. CRISPR is even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success.

It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size looking out 5 years.

Scope of the Report

The Global Market for CRISPR Gene Detection and Diagnostics

Application

Organism

Key Topics Covered:

1 Market Guides

1.1 CRISPR Gene Detection Markets – Strategic Situation Analysis

1.2 Guide for Executives, Marketing, Sales and Business Development Staff

1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

2.1 Methodology

2.1.1 Methodology

2.1.2 Sources

2.1.3 Authors

2.2 CRISPR Gene Detection Definition In This Report

2.2.1 Research

2.2.2 Clinical Laboratory

2.2.3 Consumer Diagnostics

2.2.4 Public Service

2.2.5 Other

2.3 CRISPR

2.3.1 What is CRISPR?

2.3.2 What is Gene Detection?

2.3.3 The CRISPR Family

2.3.4 Sensitivity of CRISPR

2.4 Chromosomes, Genes and Epigenetics

2.4.1 Chromosomes

2.4.2 Genes

2.4.3 Epigenetics

2.5 Market Definition

2.5.1 Revenue Market Size

2.6 Perspective: Healthcare and the IVD Industry

2.6.1 Global Healthcare Spending

2.6.2 Spending on Diagnostics

2.6.3 Important Role of Insurance for Diagnostics

3 Market Overview

3.1 Players in a Dynamic Market.

3.1.1 Academic Research Lab

3.1.2 Diagnostic Test Developer

3.1.3 Instrumentation Supplier

3.1.4 Chemical/Reagent Supplier

3.1.5 Pathology Supplier

3.1.6 Independent Clinical Laboratory

3.1.7 Public National/regional Laboratory

3.1.8 Hospital Laboratory

3.1.9 Physicians Office Lab (POLS)

3.1.10 Audit Body

3.1.11 Certification Body.

3.2 Genetic Material Detection Markets, Examples and Discussion

3.2.1 Research Markets

3.2.2 Clinical Laboratories – Accuracy, Cost and Speed

3.2.2.1 Multiplexing in the Lab and at the Point of Care

3.2.3 Consumer Diagnostics

3.2.3.1 The CRISPR Consumer

3.2.3.2 Why Consumers Like Multiplexing

3.2.4 Public Service Markets

3.2.4.1 Public Health

3.2.4.2 Public Security

3.2.4.3 Environmental Monitoring

3.2.5 AgriBio and Other Markets

4 Market Trends

4.1 Factors Driving Growth

4.1.1 Cost, Accuracy and Speed

4.1.2 The Economies of Multiplexing with Nucleic Acids

4.1.3 The New Agriculture

4.1.4 Pandemics and Pathogens

4.1.5 Health and Self – A Sea Change in Healthcare

4.2 Factors Limiting Growth

4.2.1 Ubiquitous PCR

4.2.2 The Shrinking Cost of All Things Genetic

4.2.3 Wellness has a downside

4.2.4 The Limits of Detection

5 CRISPR Recent Developments

5.1 Recent Developments – Importance and How to Use This Section

5.1.1 Importance of These Developments

5.1.2 How to Use This Section

5.2 CRISPR Enzyme Discovery Opens Diagnostic Applications

5.3 Sherlock Biosciences Adds Ambient Amplification to Diagnostic Toolkit

5.4 Rice University Adapts CRISPR Enzyme to Create Ultra-Sensitive Test

5.5 CRISPR-Based Tb Test Shows High Sensitivity

5.6 Princeton Group Develops Cas13 Assay for Point-of-Care Use

5.7 Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System

5.8 Sherlock Biosciences Raises $80M

5.9 Broad Institute Considers CRISPR Respiratory Panels to Replace PCR

5.10 Medix Biochemica Acquires MyPols Biotec

5.11 Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA

5.12 UCSD Developing At-Home Covid Test Leveraging CRISPR

5.13 Genome Diagnostics Makes €1M Investment in CRISPR Dx Startup Scope Biosciences

5.14 CRISPR SARS-CoV-2 Test Could be used for Asymptomatic Screening

5.15 Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test

5.16 Pandemic Accelerates Development of CRISPR Diagnostics

5.17 COVID Assays Use CRISPR and Smartphones

5.18 ERS Genomics Licenses CRISPR Patents to Vivlion

5.19 Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test

5.20 ERS Genomics, FASMAC to Commercialize CRISPR-Cas9

5.21 The Nobel Prize in Chemistry 2020 – CRISPR Wins

5.22 Caspr Biotech Developing COVID Dx

Key Companies

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/qxcu62

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version